



## The effect of supplementing CLOSTAT® 500 (*Bacillus subtilis* PB6) to yearling steers in a commercial feedyard on *Salmonella* spp. prevalence

### INTRODUCTION

The active microbial supplement, CLOSTAT® (Kemin Industries, Des Moines, IA) contains a unique, patented strain of *B. subtilis* PB6. Previous research with *B. subtilis* PB6 supplementation to beef steers has demonstrated positive health outcomes, as Smock et al. (2020) reported a decrease in BRD treatment rate and decreased overall disease treatment cost.<sup>1</sup> Broadway et al. (2020) indicated that *B. subtilis* PB6 supplementation improved immune response to a *Salmonella* challenge in Holstein calves and decreased the prevalence of *Salmonella* colonization in small intestinal tissues compared with non-supplemented control calves.<sup>2</sup> In high-producing dairy cows, the rate of cows culled in early lactation was reduced with *B. subtilis* PB6.<sup>3</sup>

### MATERIALS & METHODS

Steers enrolled in the study ( $n = 2,100$ ) were blocked by arrival date and BW such that arrival dates were represented equally within each BW block. Within each group of 2 eligible animals in the chute at processing, one was randomly assigned to each pen (70 steers/pen) in the block. Within blocks, pens were assigned randomly to 1 of 2 dietary treatments, thus, treatments were replicated in 15 pens. Steers were allocated into 30 contiguous, open-air, soil surface pens. Treatments, arranged in a randomized complete block design included: 1) control (CON), diets contained no supplemental bacterial or yeast direct fed microbials and were without *Bacillus subtilis* PB6; 2) CLOSTAT (CLO), diets supplemented with 0.5 g/hd/d *Bacillus subtilis* PB6 (CLOSTAT® 500, Kemin Industries, Des Moines, IA) to provide  $6.6 \times 10^9$  CFU/g of active ingredient. CLOSTAT was added to the starter and finisher diets through a micro-ingredient machine maintained by Micro Technologies (Amarillo, TX); briefly, CLO was added with water to the Roto-Mix® truck (Roto Mix, Dodge City, KS) via the micro-ingredient machine, and the diet was allowed to mix for at least 3 minutes following the addition of CLO.

Fecal samples were aseptically collected via convenience grab sampling from each pen. Fresh fecal matter was collected from multiple locations throughout a pen and composited. Each pen was analyzed in duplicate, and samples were processed in a similar manner as described by Broadway et al. (2020).<sup>2</sup> Subiliac lymph nodes were obtained from a subset of carcasses within each lot slaughtered between July 26 – September 6, 2021. Samples were processed similarly to that described by Arthur et al. (2008), and quantification and isolation were performed as described previously.<sup>4</sup>

### RESULTS

#### Prevalence of *Salmonella*

There was a difference in fecal *Salmonella* prevalence and quantity across sampling days ( $P < 0.01$ ; Figure 1). However, no differences ( $P \geq 0.35$ ) were observed in fecal *Salmonella* prevalence between CON and CLO cattle. Upon arrival, fecal *Salmonella* prevalence was 26.7% and 20% for CON and CLO respectively; however, by d 45 the percentage of prevalence positive pens had risen to 86 and 93% for CON and CLO, respectively. There was a tendency ( $P = 0.07$ ) for overall mean fecal *Salmonella* counts to be decreased in CLO (1.59 log CFU/g) compared with CON (2.04 log CFU/g; Figure 2). Similarly, there was a day effect for fecal *Salmonella* concentration ( $P < 0.01$ ) by which *Salmonella* concentrations were very few upon arrival but spiked to over 3.5 log CFU/g by d 45. Each subsequent collection from d 45 to d 180 yielded a slight decrease in overall fecal *Salmonella* concentrations. Fecal *Salmonella* concentrations were numerically reduced in CLO steers on all days with the exception of d 45 ( $P = 0.59$ ; 3.62 vs 3.88 log CFU/g for CON and CLO, respectively). The largest difference between treatments in fecal *Salmonella* concentrations occurred on d 135 ( $P = 0.01$ ; 2.50 vs. 1.23 log CFU/g for CON and CLO, respectively).

Subiliac lymph nodes were collected at harvest. There was no difference ( $P = 0.62$ ) between CON (0.22 log CFU/g) and CLO (0.19 log CFU/g) when evaluating *Salmonella* concentrations within the lymph nodes. Steers were harvested on 4 separate days, and there was a difference in lymph node *Salmonella* concentrations across harvest days (Figure 3). *Salmonella* prevalence did not differ by treatment in subiliac lymph nodes ( $P = 0.46$ ; Figure 4); however, there was a 46% decrease in the overall mean lymph node *Salmonella* prevalence (28.66% vs. 15.48% for CON and CLO, respectively). There was no difference ( $P = 0.16$ ) for lymph node *Salmonella*

prevalence between harvest dates. The percentage of *Salmonella* positive lymph nodes was numerically reduced in CLO compared to CON on all days except for harvest day 3.

## CONCLUSIONS

In a large-pen, commercial feedyard setting, supplementing CLO to feedlot steers resulted in a lower fecal prevalence of *Salmonella* compared to un-supplemented CON steers. *Bacillus subtilis* PB6 works through multifaceted modes to decrease enteric pathogen load and improve intestinal integrity. These results demonstrate that *Bacillus subtilis* PB6 is an effective active microbial for improving the overall health of feedlot cattle.

**Table 1.** Ingredient and nutrient composition of starting and finishing diets.

Ingredient, % of DM	Dietary Treatment <sup>1</sup>	
	CON	CLO
<i>Starting diet</i>		
RAMP <sup>2</sup>	100	99.98
Micro-ingredients	--	0.02
CLOSTAT® 500 <sup>3</sup> , g/T	--	0.50
<i>Composition, % of DM<sup>5</sup></i>		
Crude protein, % <sup>5</sup>	21.5	21.3
Calcium, % <sup>5</sup>	1.53	1.66
Phosphorus, % <sup>5</sup>	0.82	0.39
<i>Finishing diet</i>		
Steam flaked corn	53.67	53.63
Wet distiller's grains	19.15	19.16
Sweet Bran® Plus <sup>4</sup>	18.34	18.37
Ground corn stalks	7.45	7.44
Fat	1.36	1.37
Micro-ingredients <sup>4</sup>	0.03	0.03
CLOSTAT® 500 <sup>3</sup>	--	0.50
<i>Composition, % of DM<sup>5</sup></i>		
NE <sub>m</sub> , Mcal/kg <sup>6</sup>	2.17	2.17
NE <sub>g</sub> , Mcal/kg <sup>6</sup>	1.45	1.45
Crude protein, % <sup>5</sup>	14.7	14.8
Calcium, % <sup>5</sup>	0.79	0.82
Phosphorus, % <sup>5</sup>	0.51	5.51

<sup>1</sup>CON = control; CLO = CLOSTAT steers fed control diet supplemented with 0.5 g/hg/d *Bacillus subtilis* PB6 (CLOSTAT® 500, Kemin Industries, Des Moines, IA)


<sup>2</sup>RAMP = commercially manufactured complete starter feed (Cargill Corn Milling, Dalhart, TX), including minerals, vitamins, 20 g/T monensin (Rumensin® 90, Elanco Animal Health, Greenfield, IN) and 10 g/T tylosin (Tylan®, Elanco Animal Health).

<sup>3</sup>CLOSTAT 500, Kemin Industries, delivered through micro-ingredient machine, containing  $6.6 \times 10^9$  CFU *Bacillus subtilis* PB6.


<sup>4</sup>Micro-ingredients for finishing diet included minerals, vitamins, 42 g/T monensin (Rumensin® 90, Elanco Animal Health), 7.5 g/T tylosin (Tylan®, Elanco Animal Health), and Ractopamine-hydrochloride, 27.3 g/T the final 31 days on feed (Optaflexx®, Elanco Animal Health).

<sup>5</sup>Analysis by Servi-Tech Laboratories, Amarillo, TX.


<sup>6</sup>Formulated values based on NASEM (2016).




**Figure 1.** Fecal *Salmonella* prevalence of feedlot cattle sampled throughout the feeding period supplemented with 0.5 g/hd per day of *Bacillus subtilis* PB6, CLOSTAT® 500, Kemin Industries, Des Moines, IA, (CLO) or not (CON). Treatment:  $P = 0.35$ , Day:  $P < 0.01$ , Treatment\*Day:  $P = 0.76$ ; SEM = 5.4.



**Figure 2.** Fecal *Salmonella* concentrations from feedlot cattle sampled throughout the feeding period supplemented with 0.5 g/hd per day *Bacillus subtilis* PB6, CLOSTAT® 500, Kemin Industries, Des Moines, IA, (CLO) or not (CON). Treatment:  $P = 0.07$ , Day:  $P < 0.01$ , Treatment\*Day:  $P = 0.3$ ; SEM = 0.3.



**Figure 3.** Lymph node *Salmonella* concentrations from feedlot cattle sampled across four harvest dates that were supplemented with 0.5 g/hd per day *Bacillus subtilis* PB6, CLOSTAT® 500, Kemin Industries, Des Moines, IA, (CLO) or not (CON). Treatment:  $P = 0.62$ , Day:  $P < 0.01$ , Treatment\*Day:  $P = 0.87$ .



**Figure 4.** Lymph node *Salmonella* prevalence from feedlot cattle sampled across four harvest dates that were supplemented with 0.5 g/hd per day *Bacillus subtilis* PB6, CLOSTAT® 500, Kemin Industries, Des Moines, IA, (CLO) or not (CON). Treatment:  $P = 0.45$ , Day:  $P = 0.16$ , Treatment\*Day:  $P = 0.93$ , SEM=18.68.

## REFERENCES

1. Smock, T. M., K. L. Samuelson, J. E. Hergenreder, W. Rounds, and J. T. Richeson. 2020a. Effects of *Bacillus subtilis* PB6 and/or chromium propionate supplementation on clinical health, growth performance, and carcass traits of high-risk cattle during the feedlot receiving and finishing periods. *Transl. Anim. Sci.* 4:1-12.
2. Broadway, R. P., J. A. Carroll, N. C. Burdick Sanchez, T. R. Callaway, S. D. Lawhon, E. V. Gart, L. K. Bryan, D. J. Nisbet, H. D. Hughes, J. F. Legako, D. L. O'Connor, J. E. Hergenreder, and P. W. Rounds. 2020. *Bacillus subtilis* PB6 supplementation in weaned Holstein steers during an experimental *Salmonella* challenge. *Foodborne Pathog. Dis.* 17(8):521-528.
3. Lago, A., M. Morales, T. Haris, C. Moore, G. Camacho, K. Patel, R. Lopes, and N. Silva-del-Rio. 2021. Effect of supplementing dairy cows with *Bacillus subtilis* PB6 and/or chromium propionate on health, culling, reproductive performance and metabolic parameters. *J. Dairy Sci.* 104(Suppl. 1): P413 (Abstr.)
4. Arthur, T. M., D. M. Brichta-Harhay, J. M. Bosilevac, M. N. Guerini, N. Kalchayanand, J. E. Wells, S. D. Shackelford, T. L. Wheeler, and M. Koohmaraie. 2008. Prevalence and characterization of *Salmonella* in bovine lymph nodes potentially destined for use in ground beef. *J Food Protect.* 71(8):1685-1688.

Sweet Bran® is a registered trademark of Cargill, Incorporated, Wayzata, MN.